한빛사 논문
Jung‐Min Yi1, Il Doh2, Seok‐Hwan Lee3, Soo‐Young Kim4, Yong‐Hun Lee4, Eun‐Kyung Lee5, Soo‐Han Lee6, Byung‐Moon Choi4, Gyu‐Jeong Noh4,7
1 Department of Anesthesiology and Pain Medicine, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea
2 Center for Medical Metrology, Korea Research Institute of Standards and Science (KRISS), Daejeon, Korea
3 Center for Thermometry and Fluid Flow Metrology, Korea Research Institute of Standards and Science (KRISS), Daejeon, Korea
4 Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 Department of Statistics, Ewha Womans University, Seoul, Korea
6 New Drug Development Center, Osong Medical Innovation Foundation, Chungcheongbuk‐do, Korea
7 Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence:Byung‐Moon Choi, Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Byung‐Moon Choi and Soo‐Han Lee also contributed equally to this work as corresponding authors.
Abstract
Background
In a previous study, the modified Marsh and Schnider models respectively showed negatively‐ and positively‐biased predictions in underweight patients. To overcome this drawback, we developed a new pharmacokinetic propofol model‐the Choi model‐for use in underweight patients. In the present study, we evaluated the predictive performance of the Choi model.
Methods
Twenty underweight patients undergoing elective surgery received propofol via TCI using the Choi model. The target effect‐site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL. Arterial blood samples were obtained at least 10 minutes after achieving pseudo‐steady‐state. Predicted propofol concentrations with the modified Marsh, Schnider, and Eleveld pharmacokinetic models were obtained by simulation (Asan pump, version 2.1.3; Bionet Co. Ltd., Seoul, Korea). The predictive performance of each model was assessed by calculation of four parameters: inaccuracy, divergence, bias, and wobble.
Results
A total of 119 plasma samples were used to determine the predictive performance of the Choi model. Our evaluation showed that the pooled median (95% CI) bias and inaccuracy were 4.0 (−4.2 to 12.2) and 23.9 (17.6‐30.3), respectively. The pooled biases and inaccuracies of the modified Marsh, Schnider, and Eleveld models were clinically acceptable. However, the modified Marsh and Eleveld models consistently produced negatively biased predictions in underweight patients. In particular, the Schnider model showed greater inaccuracy at a target Ce ≥ 3 µg/mL.
Conclusion
The new propofol pharmacokinetic model (the Choi model) developed for underweight patient showed adequate performance for clinical use.
Keywords : clinical pharmacology, pharmacokinetics, propofol
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기